Total CML cases (n=100) High BMI1 expression (≥ 2.51 ) (n=52) Low BMI1 expression (<2.51 ) (n=48) P Age (years) 44 (24.0-73.0) 44 (24.0-73.0) 44 (29.0-67.0) 0.705 Sex Males 49 (49.0%) 23 (44.2%) 26 (54.2%) 0.835 females 51 (51.0%) 26 (50.0%) 25 (52.1%) WBCs (x109/l) 46 (4.4-505.0) 55.7 (4.4-505.0) 32.1 (4.5-223.0) 0.212 Eosinophils (%) 2.7 (0.2-3.8) 2.7 (0.2-3.8) 2.4 (0.2-3.6) 0.028 Basophils (%) 2.4 (2.0-5.8) 3.1 (4.0-5.8) 2.1 (2.0-5.5) 0.004 Hemoglobin concentration (g/dl) 9.8 (3.9-14.5) 9.8 (3.9-14.3) 10 (4.1-14.5) 0.950 Platelet count (x109/l) 148.5 (65.0-773.0) 153 (65.3-773.0) 138 (65.0-704.0) 0.069 Phases Chronic 66 (66.0%) 24 (46.2%) 42 (87.5%) <0.001 Accelerated 20 (20.0%) 16 (30.8%) 4 (8.3%) Blastic 14 (14.0%) 12 (23.1%) 2 (4.2%) Blastic/ Accelerated 34 (34.0%) 28 (53.8%) 6 (12.5%) <0.001*

P: significance between high versus low BMI1 expression groups. *: significance between combined blastic/accelerated phases versus chronic phase. Age, WBC,eosinophils, basophils, hemoglobin concentration and platelet count are expressed in median and range. Sex, and phases are expressed in number and percentage.WBC: White Blood Cells Count

Table 3: Demographic, laboratory and clinical characteristics in CML cases according to BMI1 expression.